Interim report January – September 2006

Biotage reports its best result ever

• The company has been strongly aimed at the integration of previously acquired units with a focus on organic growth, gross margin and cost efficiency. For the third quarter Biotage reports its best result ever, with a positive operating result as well as a positive result after tax.

• Net sales increased by 6%in the third quarter and amounted to 133.9 MSEK (126.6 MSEK the previous year). In the period January – September 2006 net sales increased by 31% to 382.9 MSEK (292.0). The strong sales increase continues. At constant exchange rates and pro-forma* the increase was approx. 11% and in the first nine months approx. 10%.

• The operating result improved by 32.0 MSEK and amounted to 11.4 MSEK (-20.6). The operating result for the first nine months amounted to -2.9 MSEK (-58.3).

• The result after tax amounted to 8.6 MSEK (-27.6) and to -8.2 MSEK (-40.3) for the first nine months.

• Earnings per share amounted to 0.10 SEK (-0.39) and to -0.09 SEK (-0.61) in the first nine months.

• The cash flow from operating activities improved considerably and amounted to 17.4 MSEK (0.9) in the third quarter and to 11.9 MSEK (-31.9) in the first nine months.

• During the third quarter two package solutions in synthesis and purification were launched, targeting industry and academy, respectively. Biotage has already received the first orders according to the new program.

For further information, please contact:

Torben Jörgensen, president and CEO, phone: +46 707 49 05 84
Mats-Olof Wallin, CFO, phone: +46 705 93 52 73


*Note: Pro-forma refers to an adjustment for the distribution of Corbett’s products in the Biosystems business area (divested in 2005), and for the Argonaut business in the Discovery Chemistry business area (acquired on June 3, 2005). The pro-forma figures have not been subject to review by the company’s accountant.